Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq:HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022.
Related news for (HILS)
- Hillstream BioPharma Announces Pricing of Public Offering
- Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic
- In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
- Hillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & Leukemias